In today’s briefing:
- Best Ideas of 2025
- LGVN: Great Position for Pivotal Year
- MIRA: Critical Testing Approved
- Windtree Therapeutics Inc – Sponsored – Impartial – Comprehensive
Best Ideas of 2025
- The range of ideas is broad. The smallest market cap is a $15MM Canadian micro-cap that is trading below its net cash, and the largest is an $25BN market cap online travel company that is gobbling up its own shares.
- We have ideas profiled from Poland, Canada, India, Austria, Argentina, Italy, and of course, the United States.
- The report will start with my personal favorite idea and then cover the additional ideas in alphabetical order.
LGVN: Great Position for Pivotal Year
- Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but continues to receive good FDA news regarding its treatment for Alzheimer’s Disease.
- The company announced improved revenue and reduced costs in 2024 results.
- Additionally, the company confirmed it has enough cash on hand to last through 2025 and that testing may be accelerated.
MIRA: Critical Testing Approved
- MIRA Pharmaceuticals(MIRA) Company Sponsored Research Report
Windtree Therapeutics Inc – Sponsored – Impartial – Comprehensive
- In Sept.
- 2024, WINT reported positive Phase 2b study results of istaroxime in early CS patients.
- To position istaroxime for Phase 3 readiness, WINT is launching a small Phase 2 study in the more severe form of CS, SCAI Stage C.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
